secwatch.observer — SEC 8-K summary
======================================

Issuer:     Lantern Pharma Inc. (LTRN)
CIK:        0001763950
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001493152-25-022134
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lantern Pharma Q3 net loss $4.2M; LP-184 Phase 1a achieves 48% clinical benefit rate
--------------------------------------------------------------------------------

- Net loss $4.2M ($0.39/shr) vs $4.5M loss in Q3 2024; cash $12.4M, runway into Q3 2026.
- LP-184 Phase 1a met all endpoints; 48% clinical benefit rate at therapeutic dose; RP2D set at 0.39 mg/kg.
- FDA Type C meeting provides regulatory path for pediatric CNS trial in ATRT; spironolactone combo strategy confirmed.
- LP-300 HARMONIC trial data presented at Japan Lung Cancer Society; Japan enrollment completed.
- RADR AI platform modules commercial-ready; predictBBB 94.1% accuracy, LBx-AI 86% accuracy for treatment response.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1763950/000149315225022134/0001493152-25-022134-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1763950/000149315225022134/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-022134

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer